Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
May 09, 2024 16:01 ET
|
Recursion Pharmaceuticals
On track to read out multiple Phase 2 clinical trials in the coming quarters, beginning in Q3 2024Performance benchmarking completed on BioHive-2, Recursion's next generation supercomputer, which will...
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results
May 09, 2024 16:01 ET
|
Interpace Biosciences, Inc.
●Q1 Revenue of $10.3 million; a 4% increase year-over-year ●Q1 Test volume up 10% year over year to record levels PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc....
Acutus Medical Reports First Quarter 2024 Financial Results
May 09, 2024 16:01 ET
|
Acutus Medical, Inc.
Acutus Medical Reports First Quarter 2024 Financial Results
CarGurus Announces First Quarter 2024 Results
May 09, 2024 16:01 ET
|
CarGurus, Inc.
1Q’24 Marketplace Revenue and QARSD growth accelerated further to 12% YoY and 14% YoY, respectively 1Q’24 Consolidated Net Income of $21.3 million, up 80% YoY; 1Q’24 Non-GAAP Adjusted EBITDA of $50.4...
Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
May 09, 2024 16:01 ET
|
Iovance Biotherapeutics, Inc.
Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Patients Enrolled Across More Than 40 Current Authorized Treatment...
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
May 09, 2024 16:01 ET
|
Eton Pharmaceuticals
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth• Acquired PKU GOLIKE®, launched Nitisinone, and submitted a...
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 16:01 ET
|
Xenon Pharmaceuticals Inc.
Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful “end-of-Phase 2” interactions with FDA in MDD; Phase...
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
May 09, 2024 16:01 ET
|
Oncternal Therapeutics
Fourth dosing cohort at 300 mg per day is fully enrolled for the Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are...
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
May 09, 2024 16:01 ET
|
Nkarta, Inc.
Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024Cash balance of $450.0 million on March 31, 2024, including cash, cash...
Stantec Announces Results of its 2024 Annual Meeting of Shareholders
May 09, 2024 16:00 ET
|
Stantec
EDMONTON, Alberta and NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- TSX, NYSE: STN Stantec Inc. (“Stantec”), a global leader in sustainable design and engineering, held its annual meeting of...
- June 15, 2024 08:57 ET MULTIMEDIA UPDATE -- Rygen Technologies Launches Next-Gen Supply Chain Solution: AI-enabled TMS
- June 14, 2024 21:21 ET Pik'r Range Picking Robot Enhances U.S. Open Experience at Pinehurst